Sera Prognostics (NASDAQ:SERA) Director Sells $11,891.95 in Stock

Key Points

• Sera Prognostics Director Sandra Aj Lawrence sold 3,899 shares of stock for a total of $11,891.95, reducing her ownership by 17.17% to 18,814 shares.
• The company reported a net margin of -30,306.48% and a revenue of $0.02 million in its latest quarterly earnings, beating expectations but reflecting ongoing financial challenges.
• Wall Street analyst Wall Street Zen downgraded Sera Prognostics from a "hold" to a "sell" rating amid ongoing struggles in stock performance and earnings.

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) Director Sandra Aj Lawrence sold 3,899 shares of the firm's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $3.05, for a total value of $11,891.95. Following the sale, the director owned 18,814 shares in the company, valued at $57,382.70. The trade was a 17.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Sera Prognostics Price Performance

NASDAQ SERA traded up $0.03 during trading hours on Friday, reaching $3.10. 44,671 shares of the stock traded hands, compared to its average volume of 105,485. The stock has a 50 day simple moving average of $2.81 and a two-hundred day simple moving average of $2.85. Sera Prognostics, Inc. has a 1 year low of $1.37 and a 1 year high of $9.13. The company has a market cap of $116.78 million, a price-to-earnings ratio of -3.65 and a beta of 1.00.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%. On average, sell-side analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded Sera Prognostics from a "hold" rating to a "sell" rating in a report on Saturday, August 9th.

Institutional Trading of Sera Prognostics

Several large investors have recently modified their holdings of SERA. Aberdeen Group plc bought a new stake in shares of Sera Prognostics in the first quarter worth about $4,563,000. AWM Investment Company Inc. grew its stake in shares of Sera Prognostics by 48.1% in the first quarter. AWM Investment Company Inc. now owns 866,837 shares of the company's stock worth $3,190,000 after purchasing an additional 281,703 shares during the last quarter. Sanders Morris Harris LLC grew its stake in shares of Sera Prognostics by 179.8% in the second quarter. Sanders Morris Harris LLC now owns 263,600 shares of the company's stock worth $730,000 after purchasing an additional 169,400 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Sera Prognostics in the fourth quarter worth about $1,285,000. Finally, Perkins Capital Management Inc. bought a new stake in shares of Sera Prognostics in the first quarter worth about $522,000. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.